Characterization of the topoisomerase I locus in human colorectal cancer

被引:21
作者
Boonsong, A
Marsh, S
Rooney, PH
Stevenson, DAJ
Cassidy, J
McLeod, HL
机构
[1] Univ Aberdeen, Dept Med & Therapeut, Inst Med Sci, Aberdeen AB25 2ZD, Scotland
[2] Univ Aberdeen, Dept Med Genet, Aberdeen AB25 2ZD, Scotland
关键词
D O I
10.1016/S0165-4608(00)00242-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
DNA topoisomerase I (topo I) is the principle target for Camptothecin and its analogues. The topo I gene is located on chromosome 20q11.2-q13.1 and variation in topo I gene copy number has been shown to have impact on the in vitro sensitivity to topoisomerase I inhibitor chemotherapy. Fluorescence in situ hybridization (FISH) rr-as used to detect and compare the TOPO I gene copy number between metaphase and interphase nuclei in a panel of 7 colorectal cancer cell lines. TOPO I gene copy number varied from 2 to 8 between cell lines, and signal in interphase nuclei demonstrated a linear relationship with that detected in metaphase nuclei. The structure of gene amplification included isochromosome formation, amplicon extension, and marker chromosome generation. Comparative genomic hybridization (CGH) was then used to further define the region of gain on chromosome 20. The region of gain contained the topo I gene and involved nearly all of 20q in most cases. This demonstrates a high degree of intrinsic variation in topo I gene copy number and the involvement of a 20q amplicon in colorectal cancer, which may have important implications for colorectal tumorigenesis and the use of chemotherapy. (C) 2000 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:56 / 60
页数:5
相关论文
共 15 条
[1]   Positional cloning of ZNF217 and NABC1:: Genes amplified at 20q13.2 and overexpressed in breast carcinoma [J].
Collins, C ;
Rommens, JM ;
Kowbel, D ;
Godfrey, T ;
Tanner, M ;
Hwang, S ;
Polikoff, D ;
Nonet, G ;
Cochran, J ;
Myambo, K ;
Jay, KE ;
Froula, J ;
Cloutier, T ;
Kuo, WL ;
Yaswen, P ;
Dairkee, S ;
Giovanola, J ;
Hutchinson, GB ;
Isola, J ;
Kallioniemi, OP ;
Palazzolo, M ;
Martin, C ;
Ericsson, C ;
Pinkel, D ;
Albertson, D ;
Li, WB ;
Gray, JW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (15) :8703-8708
[2]  
Fukushige S, 1997, GENE CHROMOSOME CANC, V19, P161, DOI 10.1002/(SICI)1098-2264(199707)19:3<161::AID-GCC5>3.0.CO
[3]  
2-W
[4]   EUKARYOTIC DNA TOPOISOMERASES-I [J].
GUPTA, M ;
FUJIMORI, A ;
POMMIER, Y .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1995, 1262 (01) :1-14
[5]  
HUSAIN I, 1994, CANCER RES, V54, P539
[6]   IDENTIFICATION OF GAINS AND LOSSES OF DNA-SEQUENCES IN PRIMARY BLADDER-CANCER BY COMPARATIVE GENOMIC HYBRIDIZATION [J].
KALLIONIEMI, A ;
KALLIONIEMI, OP ;
CITRO, G ;
SAUTER, G ;
DEVRIES, S ;
KERSCHMANN, R ;
CAROLL, P ;
WALDMAN, F .
GENES CHROMOSOMES & CANCER, 1995, 12 (03) :213-219
[7]  
KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V258, P818
[8]   LOCALIZATION OF THE ACTIVE TYPE-I DNA TOPOISOMERASE GENE ON HUMAN CHROMOSOME-20Q11.2-13.1, AND 2 PSEUDOGENES ON CHROMOSOME-1Q23-24 AND CHROMOSOME-22Q11.2-13.1 [J].
KUNZE, N ;
YANG, GC ;
JIANG, ZY ;
HAMEISTER, H ;
ADOLPH, S ;
WIEDORN, KH ;
RICHTER, A ;
KNIPPERS, R .
HUMAN GENETICS, 1989, 84 (01) :6-10
[9]   Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity [J].
McLeod, HL ;
Keith, WN .
BRITISH JOURNAL OF CANCER, 1996, 74 (04) :508-512
[10]   TOPOISOMERASE-I AND TOPOISOMERASE-II ACTIVITY IN HUMAN BREAST, CERVIX, LUNG AND COLON-CANCER [J].
MCLEOD, HL ;
DOUGLAS, F ;
OATES, M ;
SYMONDS, RP ;
PRAKASH, D ;
VANDERZEE, AGJ ;
KAYE, SB ;
BROWN, R ;
KEITH, WN .
INTERNATIONAL JOURNAL OF CANCER, 1994, 59 (05) :607-611